Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02019277) enrolled 50 participants, all of whom received a combination of three medicines: trastuzumab, pertuzumab, and a taxane (a type of chemotherapy). The trial had one treatment group only — there was no comparison or placebo group. Of the 50 who started, 38 completed the study and 12 did not. The trial was primarily measuring how many participants experienced unwanted medical events (called adverse events) during treatment, and secondarily tracking things like how tumours responded to treatment and how long participants went without their disease getting worse. The reported data shows that 100% of participants experienced at least one adverse event of any kind during the study, and 54% experienced what was classified as a serious adverse event — meaning an event that led to hospitalisation, was life-threatening, caused lasting disability, or was otherwise considered significant. On the tumour response measures, 73.3% of participants were recorded as having their tumour either disappear completely or shrink by a meaningful amount. The reported data shows that 60% of participants experienced disease progression (their cancer grew or spread) or died during the study period. The median time from the start of treatment until disease progression or death was reported as approximately 17 months (median meaning half the participants reached this point sooner and half later). Around 18% of participants died during the study from any cause. The median overall survival figure — how long participants lived from the start of treatment — was not able to be calculated and was reported as not available. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Breast Cancer Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Your breast cancer tumor tests positive for a protein called HER2 (confirmed by lab testing of the tumor).
- You have been diagnosed with breast cancer that has spread to other parts of the body (metastatic), confirmed by a tissue or cell sample, with at least one area that can be measured or tracked.
- You are well enough to carry out daily activities at a certain level (your doctor will assess this using a standard scale, and the required level depends on which chemotherapy you would receive).
- Your heart is pumping well enough, confirmed by a heart scan (ECHO or MUGA), showing at least 50% function before starting treatment.
- You have previously had HER2-targeted therapy before your cancer spread (before or after surgery) — this is allowed.
- You may be able to take hormone therapy alongside this trial, following your hospital's guidelines, but not at the same time as the chemotherapy used in this trial.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have already received non-hormonal treatments (such as chemotherapy) aimed at your metastatic breast cancer.
- You have a history of other cancers, unless it was an early-stage cervical or skin cancer that was fully treated, another cancer you have been free of for at least 5 years, or an early form of breast cancer (DCIS) that was fully treated.
- You are pregnant, breastfeeding, or have a positive pregnancy test within 7 days before starting treatment (confirm with trial site).
- You have severe nerve damage in your hands or feet (a condition called peripheral neuropathy at grade 3 or higher).
- Scans show your cancer has spread to the brain or spinal cord, unless it has been treated, has been stable for at least 3 months, and you no longer need steroid medication for it.
- You have other serious illnesses that could interfere with treatment, including serious lung conditions.
- Your kidneys, liver, or other organs are not working well enough (confirm specific requirements with trial site).
- You have serious heart problems that would make one of the trial drugs (trastuzumab) unsafe for you.
- You have severe difficulty breathing while at rest, or you need extra oxygen to breathe.
- You are currently taking part in another clinical trial using an experimental cancer treatment, or have done so within 28 days before starting this trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 13 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Percentage of Participants With Adverse Events (AEs) and Serious AEs; Percentage of Participants With AEs by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0 Intensity Grades; Percentage of Participants With AEs Leading to Premature Discontinuation of Investigational Medicinal Products (IMPs); Percentage of Participants With AEs of Suspected Cardiac Origin, by New York Heart Association Classification (NYHA); Percentage of Participants With Left Ventricular Ejection Fraction (LVEF) Below 50%
Other options
Data last synced from ClinicalTrials.gov: 1 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.